Blood Reviews最新文献_第9页

Down syndrome and leukemia: An insight into the disease biology and current treatment options 唐氏综合症和白血病:对疾病生物学和当前治疗方案的洞察。

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101154

Sonali P. Barwe, E. Anders Kolb, Anilkumar Gopalakrishnapillai

{"title":"Down syndrome and leukemia: An insight into the disease biology and current treatment options","authors":"Sonali P. Barwe, E. Anders Kolb, Anilkumar Gopalakrishnapillai","doi":"10.1016/j.blre.2023.101154","DOIUrl":"10.1016/j.blre.2023.101154","url":null,"abstract":"<div>Children with Down syndrome (DS) have a 10- to 20-fold greater predisposition to develop acute leukemia compared to the general population, with a skew towards myeloid leukemia (ML-DS). While ML-DS is known to be a subtype with good outcome, patients who relapse face a dismal prognosis. Acute lymphocytic leukemia in DS (DS-ALL) is considered to have poor prognosis. The relapse rate is high in DS-ALL compared to their non-DS counterparts. We have a better understanding about the mutational spectrum of DS leukemia. Studies using animal, embryonic stem cell- and induced pluripotent stem cell-based models have shed light on the mechanism by which these mutations contribute to disease initiation and progression. In this review, we list the currently available treatment strategies for DS-leukemias along with their outcome with emphasis on challenges with chemotherapy-related toxicities in children with DS. We focus on the mechanisms of initiation and progression of leukemia in children with DS and highlight the novel molecular targets with greater success in preclinical trials that have the potential to progress to the clinic.</div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101154"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] “激活丙酮酸激酶作为罕见溶血性贫血的治疗选择:对一种旧酶的新认识”的勘误表[Blood Rev. 2023 Sep:61:101103]。

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101160

Myrthe J. van Dijk , Jonathan R.A. de Wilde , Marije Bartels , Kevin H.M. Kuo , Andreas Glenthøj , Minke A.E. Rab , Eduard J. van Beers , Richard van Wijk

引用次数: 0

Chromosomal defects in multiple myeloma 多发性骨髓瘤的染色体缺陷

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2024.101168

Sarah E. Clarke , Kathryn A. Fuller , Wendy N. Erber

{"title":"Chromosomal defects in multiple myeloma","authors":"Sarah E. Clarke , Kathryn A. Fuller , Wendy N. Erber","doi":"10.1016/j.blre.2024.101168","DOIUrl":"10.1016/j.blre.2024.101168","url":null,"abstract":"<div>Multiple myeloma is a plasma cell neoplasm driven by primary (e.g. hyperdiploidy; IGH translocations) and secondary (e.g. 1q21 gains/amplifications; del(17p); MYC translocations) chromosomal events. These are important to detect as they influence prognosis, therapeutic response and disease survival. Currently, cytogenetic testing is most commonly performed by interphase fluorescence in situ hybridisation (FISH) on aspirated bone marrow samples. A number of variations to FISH methodology are available, including prior plasma cell enrichment and incorporation of immunophenotypic plasma cell identification. Other molecular methods are increasingly being utilised to provide a genome-wide view at high resolution (e.g. single nucleotide polymorphism (SNP) microarray analysis) and these can detect abnormalities in most cases. Despite their wide application at diagnostic assessment, both FISH and SNP-array have relatively low sensitivity, limiting their use for identification of prognostically significant low-level sub-clones or for disease monitoring. Next-generation sequencing is increasingly being used to detect mutations and new FISH techniques such as by flow cytometry are in development and may address some of the current test limitations. Here we review the primary and secondary cytogenetic aberrations in myeloma and discuss the range of techniques available for their assessment.</div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101168"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X24000018/pdfft?md5=4cbbd86c290549e3b2d6d8e05c96d26e&pid=1-s2.0-S0268960X24000018-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139096351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing high dose melphalan 优化大剂量美法仑

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101162

Gunjan Shah, Sergio Giralt, Parastoo Dahi

{"title":"Optimizing high dose melphalan","authors":"Gunjan Shah, Sergio Giralt, Parastoo Dahi","doi":"10.1016/j.blre.2023.101162","DOIUrl":"10.1016/j.blre.2023.101162","url":null,"abstract":"<div>Melphalan, has been a major component of myeloma therapy since the 1950s. In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen used due to its potent anti-myeloma effects and manageable toxicities. Common toxicities associated with HDM include myelosuppression, gastrointestinal issues, and mucositis. Established approaches to reduce these toxicities encompass dose modification, nausea prophylaxis with 5HT3 receptor antagonists, cryotherapy, amifostine use, and growth factors. Optimization of melphalan exposure through personalized dosing and its combination with other agents like busulfan, or bendamustine show promise. Propylene glycol-free melphalan (Evomela) represents a novel formulation aiming to enhance drug stability and reduce adverse effects. This review explores strategies to enhance the efficacy and mitigate the toxicity of HDM in multiple myeloma. Future directions involve exploring these strategies in clinical trials to improve the safety and efficacy of HDM, thereby enhancing outcomes for multiple myeloma patients undergoing autologous HCT.</div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101162"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138576170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From microscope to micropixels: A rapid review of artificial intelligence for the peripheral blood film 从显微镜到微像素:外周血膜人工智能的快速回顾。

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101144

Bingwen Eugene Fan , Bryan Song Jun Yong , Ruiqi Li , Samuel Sherng Young Wang , Min Yi Natalie Aw , Ming Fang Chia , David Tao Yi Chen , Yuan Shan Neo , Bruno Occhipinti , Ryan Ruiyang Ling , Kollengode Ramanathan , Yi Xiong Ong , Kian Guan Eric Lim , Wei Yong Kevin Wong , Shu Ping Lim , Siti Thuraiya Binte Abdul Latiff , Hemalatha Shanmugam , Moh Sim Wong , Kuperan Ponnudurai , Stefan Winkler

{"title":"From microscope to micropixels: A rapid review of artificial intelligence for the peripheral blood film","authors":"Bingwen Eugene Fan , Bryan Song Jun Yong , Ruiqi Li , Samuel Sherng Young Wang , Min Yi Natalie Aw , Ming Fang Chia , David Tao Yi Chen , Yuan Shan Neo , Bruno Occhipinti , Ryan Ruiyang Ling , Kollengode Ramanathan , Yi Xiong Ong , Kian Guan Eric Lim , Wei Yong Kevin Wong , Shu Ping Lim , Siti Thuraiya Binte Abdul Latiff , Hemalatha Shanmugam , Moh Sim Wong , Kuperan Ponnudurai , Stefan Winkler","doi":"10.1016/j.blre.2023.101144","DOIUrl":"10.1016/j.blre.2023.101144","url":null,"abstract":"<div>Artificial intelligence (AI) and its application in classification of blood cells in the peripheral blood film is an evolving field in haematology. We performed a rapid review of the literature on AI and peripheral blood films, evaluating the condition studied, image datasets, machine learning models, training set size, testing set size and accuracy. A total of 283 studies were identified, encompassing 6 broad domains: malaria (n = 95), leukemia (n = 81), leukocytes (n = 72), mixed (n = 25), erythrocytes (n = 15) or Myelodysplastic syndrome (MDS) (n = 1). These publications have demonstrated high self-reported mean accuracy rates across various studies (95.5% for malaria, 96.0% for leukemia, 94.4% for leukocytes, 95.2% for mixed studies and 91.2% for erythrocytes), with an overall mean accuracy of 95.1%. Despite the high accuracy, the challenges toward real world translational usage of these AI trained models include the need for well-validated multicentre data, data standardisation, and studies on less common cell types and non-malarial blood-borne parasites.</div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101144"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era 揭示血液学肿瘤的种系易感性:在基因组时代导航复杂性。

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101143

Joaquín Jerez , Marta Santiago

引用次数: 0

Αlpha-thalassemia: A practical overview α-地中海贫血：实用概述

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101165

Khaled M. Musallam , M. Domenica Cappellini , Thomas D. Coates , Kevin H.M. Kuo , Hanny Al-Samkari , Sujit Sheth , Vip Viprakasit , Ali T. Taher

{"title":"Αlpha-thalassemia: A practical overview","authors":"Khaled M. Musallam , M. Domenica Cappellini , Thomas D. Coates , Kevin H.M. Kuo , Hanny Al-Samkari , Sujit Sheth , Vip Viprakasit , Ali T. Taher","doi":"10.1016/j.blre.2023.101165","DOIUrl":"10.1016/j.blre.2023.101165","url":null,"abstract":"<div>α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and thus varying degrees of ineffective erythropoiesis, decreased red blood cell (RBC) survival, chronic hemolytic anemia, and subsequent comorbidities. Clinical presentation varies depending on the genotype, ranging from a silent or mild carrier state to severe, transfusion-dependent or lethal disease. Management of patients with α-thalassemia is primarily supportive, addressing either symptoms (eg, RBC transfusions for anemia), complications of the disease, or its transfusion-dependence (eg, chelation therapy for iron overload). Several novel therapies are also in development, including curative gene manipulation techniques and disease modifying agents that target ineffective erythropoiesis and chronic hemolytic anemia. This review of α-thalassemia and its various manifestations provides practical information for clinicians who practice beyond those regions where it is found with high frequency.</div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101165"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001352/pdfft?md5=bfdf3f2cb6cd0f3a1be7f480cd63530b&pid=1-s2.0-S0268960X23001352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139092770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iron deficiency anemia among women: An issue of health equity 妇女缺铁性贫血:健康公平问题。

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101159

Grace H. Tang , Michelle Sholzberg

引用次数: 0

Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances 特发性多中心Castleman病:最新的诊断和治疗进展

IF 7.4 2区医学

Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101161

Evan Lang , Frits van Rhee

引用次数: 0

Richter's transformation: Transforming the clinical landscape 里克特的转变改变临床格局